2C-B: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Cut uncitable claims from 2C-B history: remove Eroxan brand name and the South Africa / Medicines Control Council passage; keep only what Papaseit 2018 and the DEA rules support |
MDElliottMD (talk | contribs) Retract the citation-driven cut: restore the Europe/Eroxan/South Africa history with [citation needed] markers per Mark's rule (Claude-generated uncitable claims are flagged, not deleted) |
||
| Line 21: | Line 21: | ||
| history = The compound that became 2C-B emerged from Shulgin's systematic exploration of the structure-activity relationships of mescaline analogs, a program he had begun in the mid-1960s. Shulgin's hypothesis was that modifications to the trimethoxyphenethylamine skeleton might yield compounds active at lower doses than mescaline's, with subjective profiles that varied in characteristic ways with the substituent at the 4-position of the phenyl ring. 2C-B, with bromine at the 4-position, was one of the most striking results. The first published description appeared in 1975 in Psychopharmacology Communications, the short-lived journal that was one of the few outlets willing to publish Shulgin's work in that era.<ref name="shulgin1975">Shulgin AT, Carter MF. Centrally active phenethylamines. Psychopharmacology Communications. 1975;1(1):93-98.</ref> | | history = The compound that became 2C-B emerged from Shulgin's systematic exploration of the structure-activity relationships of mescaline analogs, a program he had begun in the mid-1960s. Shulgin's hypothesis was that modifications to the trimethoxyphenethylamine skeleton might yield compounds active at lower doses than mescaline's, with subjective profiles that varied in characteristic ways with the substituent at the 4-position of the phenyl ring. 2C-B, with bromine at the 4-position, was one of the most striking results. The first published description appeared in 1975 in Psychopharmacology Communications, the short-lived journal that was one of the few outlets willing to publish Shulgin's work in that era.<ref name="shulgin1975">Shulgin AT, Carter MF. Centrally active phenethylamines. Psychopharmacology Communications. 1975;1(1):93-98.</ref> | ||
The compound entered psychotherapeutic underground practice in the late 1970s, where it gained a reputation as a potential adjunct to psychotherapy.<ref name="papaseit2018"/> Interest grew particularly after MDMA was placed in Schedule I, on an emergency basis in 1985 and permanently in 1988,<ref name="blok2020">Blok G. [From Adam to ecstacy; legal use of MDMA in the 1970s and 1980s]. Tijdschrift voor Psychiatrie. 2020;62(8):702-706. PMID 32816299.</ref> removing that medicine from the limited circle of therapists who had been using it adjunctively. 2C-B remained legal in the United States until 1994 | The compound entered psychotherapeutic underground practice in the late 1970s, where it gained a reputation as a potential adjunct to psychotherapy.<ref name="papaseit2018"/> Interest grew particularly after MDMA was placed in Schedule I, on an emergency basis in 1985 and permanently in 1988,<ref name="blok2020">Blok G. [From Adam to ecstacy; legal use of MDMA in the 1970s and 1980s]. Tijdschrift voor Psychiatrie. 2020;62(8):702-706. PMID 32816299.</ref> removing that medicine from the limited circle of therapists who had been using it adjunctively. 2C-B remained legal in the United States until 1994<ref name="fr1994"/> and, for a window of years, in much of Europe. [citation needed] During that period it was used by some therapists as an MDMA-adjacent option for couples and individual work. [citation needed] It was sold commercially as an aphrodisiac under the brand name Nexus<ref name="papaseit2018"/> and, in some accounts, the name Eroxan, with commercial sale dated to the late 1980s. [citation needed] As Nexus, 2C-B became particularly identified with South Africa, where it had a brief and conspicuous run as a legally sold aphrodisiac in the early 1990s before the South African Medicines Control Council scheduled it. [citation needed] | ||
{{ShulginsCorner | {{ShulginsCorner | ||